Evaxion Biotech A/S (EVAX) — Analyst outlook / Analyst consensus target is. Based on 4 analyst ratings, the consensus is bullish — 4 Buy.
The consensus price target is $10.50 (low: $10.00, high: $11.00), representing an upside of 153.6% from the current price $4.14.
Analysts estimate Earnings Per Share (EPS) of $-0.63 and revenue of $0.00B for the next fiscal year.
Earnings Per Share (EPS) track record: 2024: actual $-2.00 vs est $-0.63 (missed -215.6%). 2025: actual $-1.21 vs est $-0.07 (missed -1631%). Analyst accuracy: 19%.
EVAX Stock — 12-Month Price Forecast
$10.50
▲ +153.62% Upside
Average Price Target
Based on 4 Wall Street analysts offering 12-month price targets for Evaxion Biotech A/S, the average price target is $10.50, with a high forecast of $11.00, and a low forecast of $10.00.
The average price target represents a +153.62% change from the last price of $4.14.
Highest Price Target
$11.00
Average Price Target
$10.50
Lowest Price Target
$10.00
EVAX Analyst Ratings
Buy
Based on 4 analysts giving stock ratings to Evaxion Biotech A/S in the past 3 months
EPS Estimates — EVAX
19%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual –$2.00
vs Est –$0.63
▼ 68.3% off
2025
Actual –$1.21
vs Est –$0.07
▼ 94.2% off
Profitability Outlook
Company has been making losses in all recent fiscal years. EPS is improving but still negative. Analysts expect losses to continue near-term.
Revenue Estimates — EVAX
18%
Analyst Accuracy
Inaccurate
2 years compared
Actual vs Estimate
2024
Actual $0.003B
vs Est $0.001B
▲ 79.2% off
2025
Actual $0.008B
vs Est $0.001B
▲ 84.6% off
Revenue Trend
Revenue has been relatively flat. Analysts expect stable revenue going forward.
